Essential Agreements in Biotech Start-ups

For a biotech start-up, success is ultimately measured by bringing a drug to market. This entails many things, ranging from science to development to strategy to finance and more. But the basis for all of this, in the end, comes down to legal agreements that enable a company to operate.

This event, organized with Vischer and Walder Wyss, will focus on all the main legal agreements for a drug development company to operate. We will give an input to what needs to be in place for the various steps along the life of a biotech start-up:

• Shareholder’s Agreements
• Licensing and Collaborations Agreements
• Research Agreements
• Convertible Loan Agreements
• Investment Agreements, Cap Tables and Valuation
• Mergers & Acquisitions Agreements

We will dive deeper into one or two topics based on your interests. To help us tailor the session, please take a moment to vote in our anonymous poll here.

Speakers:
• Christoph Burckhardt, Attorney at Law & Policymaker, Walder Wyss Ltd.
• Simon, Olstein, Attorney at Law & Senior Associate, Walder Wyss Ltd.
• Robert von Rosen, Partner Walder Wyss Ltd.
• Vincent Reardon, Managing Associate, VISCHER AG
• Natacha Tang, Associate, VISCHER AG
• Christian Wyss, Partner, VISCHER AG

Participation is free; however, registration is required before the event.